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Abstract 
Alzheimer disease (AD) is a growing problem for aging 
populations worldwide. Despite significant efforts, no 
therapeutics are available that stop or slow progression of AD, 10 
which has driven interest in the basic causes of AD and search for 
new therapeutic strategies. Longitudinal studies have clarified 
that defects in glucose metabolism occur in patients exhibiting 
Mild Cognitive Impairment (MCI) and glucose hypometabolism 
is an early pathological change within AD brain. Further, type 2 15 
diabetes mellitus (T2DM) is a strong risk factor for the 
development of AD. These findings have stimulated interest in 
the possibility that disrupted glucose regulated signaling within 
the brain could contribute to the progression of AD. One such 
process of interest is the addition of O-linked N-20 
acetylglucosamine (O-GlcNAc) residues onto nuclear and 
cytoplasmic proteins within mammals. O-GlcNAc is notably 
abundant within brain and its presence on hundreds of proteins 
including several, such as tau and the amyloid precursor protein, 
which are involved in the pathophysiology AD. The cellular 25 
levels of O-GlcNAc are coupled to nutrient availability through 
the action of just two enzymes. O-GlcNAc transferase (OGT) is 
the glycosyltransferase that acts to install O-GlcNAc onto 
proteins and O-GlcNAcase (OGA) is the glycosylhydrolase that 
acts to remove O-GlcNAc from proteins. Uridine diphosphate N-30 
acetylglucosamine (UDP-GlcNAc) is the substrate for OGT and 
its levels vary with cellular glucose availability because it is 
generated from glucose through the hexosamine biosynthetic 
pathway (HBSP). Within the brains of AD patients O-GlcNAc 
levels have been found to be decreased and aggregates of tau 35 
appear to lack O-GlcNAc entirely.  Accordingly, glucose 
hypometabolism within the brain may result in disruption of the 
normal functions of O-GlcNAc within the brain and thereby 
contribute to downstream neurodegeneration. While this 
hypothesis remains largely speculative, recent studies using 40 
different mouse models of AD have demonstrated the protective 
benefit of pharmacologically increased brain O-GlcNAc levels. In 
this review we summarize the state of knowledge in the area of 
O-GlcNAc as it pertains to AD while also addressing some of the
basic biochemical roles of O-GlcNAc and how these might 45 
contribute to protecting against AD and other neurodegenerative 
diseases. 
Introduction 
Alzheimer Disease (AD) is the most common neurodegenerative 
disease. This progressive disease leads initially to cognitive 50 
impairment and ultimately to death. The incidence of AD within 
populations worldwide is steadily increasing, in large part 
because age is the largest risk factor.  Approximately 26 million 
people suffer from AD and this number is projected to quadruple 
by 2050. Given the absence of any disease modifying 55 
therapeutics, the disease poses a major challenge to societies who 
must be prepared to cope with the growing amount of intensive 
patient care required by the increasing number of AD patients. 
These facts have stimulated great interest in the causes and 
mechanisms driving AD as well as an allied search for potential 60 
strategies that might slow or halt progression of the disease. 
The microtubule-associated protein tau (tau) and the amyloid 
precursor protein (APP) are the two proteins that give rise to the 
chief pathological hallmarks of AD; extracellular neuritic (senile) 
plaques composed of amyloid-β peptide, which are derived from 65 
the amyloid precursor protein (APP), and intracellular 
neurofibrillary tangles (NFTs), which are formed from the 
microtubule associated protein tau (tau). The post-translational 
modification of these proteins has emerged as a topic of 
considerable interest since various modifications have been found 70 
to alter the toxicity of these proteins. Consequently, the ability to 
manipulate the modification state of these proteins and other 
upstream factors may offer routes to decrease their toxicity in 
AD. Accordingly, an increasing number of enzymatic and non-
enzymatic post-translational modifications have been found on 75 
these two proteins and several of these are well implicated in AD 
pathology (for review see1, 2). Among these post-translational 
modifications, it has emerged that both APP and tau are 
enzymatically modified with N-acetyl-D-glucosamine (GlcNAc) 
residues O-linked to the hydroxyl groups of serine and threonine 80 
residues (O-GlcNAc). The O-GlcNAc modification and its 
potential involvement in AD will be the chief focus of this 
review.  
O-GlcNAc is a non-canonical form of protein glycosylation
that occurs within the nucleus and cytoplasm of multicellular 85 
eukaryotes. The O-GlcNAc modification, as it is commonly 
referred to, has been found on diverse families of proteins 
ranging from low abundance transcription factors through to 
common cytoskeletal proteins3. This modification has emerged as 
the focus of a field of increasingly broad scope in the last number 90 
of years, not only because of the growing number of proteins on 
which it is found, but also because of the number of important 
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cellular processes in which these proteins participate. The fact 
that both tau and APP bear the O-GlcNAc modification and are 
critically involved in the development of AD has raised the 
possibility that O-GlcNAc may play a role in the pathogenesis of 
this disease. Using a similar rationale, the presence of O-GlcNAc 5 
on other proteins such as α-synuclein4, which is a component of 
Lewy bodies found most notably in Parkinson’s disease5 (PD), as 
well as superoxide dismutase (SOD)6 and neurofilament 
proteins7, which are involved in ALS, suggests O-GlcNAc may 
play roles in a variety of neurodegenerative diseases. Over recent 10 
years, a number of studies have taken the first steps beyond 
identifying sites of O-GlcNAc on proteins involved in 
neurodegeneration and have moved to unravel the ways in which 
this enigmatic carbohydrate modification alters the functions of 
these proteins in both homeostasis and disease. The purpose of 15 
this review is to broadly highlight the state of knowledge 
regarding the biochemical properties of O-GlcNAc, with specific 
emphasis on the presence and potential functions of O-GlcNAc 
on both tau and APP, as well as to discuss the potential 
contributions of misregulated O-GlcNAc in the pathogenesis of 20 
AD. Further, based on the presence of O-GlcNAc on other 
proteins involved in neurodegenerative diseases, we speculate on 
more general roles for O-GlcNAc in neurodegeneration and the 
therapeutic potential of altering protein O-GlcNAc levels. 
1. The O-GlcNAc modification25 
The discovery, in 1984 by Torres and Hart, that O-linked N-
acetyl-D-glucosamine (GlcNAc) could be found within the inside 
of lymphocytes marked a paradigm shift in the study of 
carbohydrates and their biology8. This surprising observation was 
the first, and still the only, demonstration of nucleocytoplasmic 30 
protein glycosylation within metazoans. This modification later 
became known as the O-GlcNAc post-translational modification. 
O-GlcNAc stands in contrast to more widely recognized forms of
glycosylation, such as N-linked glycosylation which is found
exclusively within the secretory compartments, the outside of the 35 
cell, and in the extracellular milieu9. O-GlcNAc has now been 
identified on a diverse array of proteins which localize within the 
cytoplasm, nucleus, and mitochondria8. Proteins which bear the 
O-GlcNAc posttranslational modification are involved in such
diverse processes as regulation of gene expression10, translation11,40 
and metabolism12. The addition of O-GlcNAc to protein
substrates is carried out by just one glycosyltransferase that is
referred to as uridine diphosphate-N-acetyl-D-glucosamine:
polypeptidyl transferase (OGT). This enzyme uses the donor
sugar, uridine 5'-diphospho-N-acetylglucosamine (UDP-45 
GlcNAc), to transfer GlcNAc to serine or threonine residues13, 14. 
O-GlcNAc can be removed from proteins by a glycoside
hydrolase called O-GlcNAcase (OGA), which catalyses the
hydrolytic cleavage of GlcNAc off from modified proteins15, 16
(Figure 1). 50 
 The enzymatic addition and removal of O-GlcNAc from 
proteins can occur several times during the lifetime of a protein 
and, though the turnover rates have only been described on a 
small number of proteins, the half-life of O-GlcNAc on studied 
protein appears to be several hours17, 18. O-GlcNAc appears to be 55 
completely conserved within multicellular eukaryotes and OGA 
and OGT are highly conserved nucleocytoplasmically localized 
enzymes, suggesting O-GlcNAc plays ancient and fundamental 
roles in cells. 
60 
1.1. Tissue and sub-cellular localization 
To date no detailed comparative analysis of the abundance of O-
GlcNAc at the tissue level has been published. However, the 
mRNA expression levels of the enzymes which install and 65 
remove O-GlcNAc, OGT and OGA, have been extensively 
studied within mammals at the tissue level. OGT is universally 
expressed in all tissues examined, with the highest level of 
expression in pancreas and brain13, 14. Additionally, one study has 
shown that the level of OGT activity is ten-fold higher in brain 70 
than peripheral tissues19. OGA mRNA expression has also been 
detected in all tissues studied, where the expression level was by 
far the highest in the brain16. Brain regions showing particularly 
high levels of OGT expression and O-GlcNAc include the 
cerebellar cortex and hippocampus20, 21. Interestingly, O-GlcNAc 75 
is also present at all stages of development of the embryonic 
brain and its levels do not appear to change between the 
embryonic, post-natal, and adult stages in mice22. Collectively, 
these studies suggest that the O-GlcNAc modification may play a 
particularly important role within mammalian brain. This 80 
possibility is further supported by an elegant tissue-specific gene 
knock-out study performed by Marth and co-workers. These 
investigators bred mice containing an OGT gene flanked by two 
lox-p sites (OGTF). Crossing these OGTF mice with mice 
expressing a cre-recombinanse under control of the synapsin-1 85 
promoter (Syn1-CRE), led to both central and peripheral neuron-
specific expression of the cre-recombinase and corresponding 
loss of OGT. These OGTF/Syn1-CRE offspring were found with 
lower frequency, were considerably smaller, had abnormal 
locomotor ability, and none survived longer than 10 days. No 90 
histological examination of the OGTF/Syn1-CRE mice were 
performed in this study so it is unknown whether these effects 
were due specifically to the death of neurons. Biochemical 
analyses, however, revealed that tau is abnormally 
hyperphosphorylated within both the brain and spinal cord, 95 
suggesting O-GlcNAcylation may play a role in the regulation of 
tau phosphorylation. The deleterious effect of losing OGT and O-
GlcNAc within these mice is also consistent with the high levels 
of O-GlcNAc and OGT within the brain playing essential roles in 
homeostasis. At the cellular level within brain, particular 100 
attention has been directed toward O-GlcNAc and OGT levels in 
neurons. O-GlcNAc has been shown to be highly abundant at the 
nodes of Ranvier,23 and especially high at the the termini of 
Figure 1. O-GlcNAc is added by OGT and removed by OGA. A 
glycosyltransferase, uridine diphospho-N-acetylglucosamine:
polypeptidyl-β-N-acetylglucosaminyltransferase, OGT transfers 
GlcNAc from the donor sugar UDP-GlcNAc to target proteins. 
Conversely, a glycoside hydrolase, O-GlcNAcase or OGA catalyzes 
the hydrolytic cleavage of GlcNAc off of modified proteins. 
neurons24. This abundance at nerve termini has stimulated interest 
from analytical biochemists, who have gone on to identify 
hundreds of O-GlcNAc modified proteins in synaptosomes and 
identify hundreds of sites on these proteins25-27. In terms of brain 
region-specific O-GlcNAc levels, it has been noted that O-5 
GlcNAc is particularly abundant in the Purkinje neurons of the 
cerebellar cortex20 within mice as well as in radial glia of 
developing chicken optic tecta28. Little however, is known about 
how the roles of O-GlcNAc might differ between the different 
cell types of the brain and this remains a fertile area for 10 
investigation. 
1.2. O-GlcNAc transferase (OGT) 
OGT in mammals is encoded by a single gene located on the X 
chromosome29 and it has been shown that deletion of the ogt gene 
is embryonic lethal in mice29. This glycosyltransferase was first 15 
cloned by the Hanover and Hart groups13, 14. These authors 
demonstrated that the ogt gene is highly conserved across a 
number of eukaryotes from C. elegans to humans13, 14. The 
primary product of the ogt gene is a 1036 amino acid protein of 
~110 kDa13, 14 that is found in both the nucleus and the cytosol 20 
(referred to as ncOGT). This variant is the best studied and it has 
been shown to use an ordered bi-bi catalytic mechanism and 
display considerable variability in its Km values for protein 
substrates. Notably, the Km for UDP-GlcNAc for different protein 
substrates varies from single digit micromolar to high double 25 
digit micromolar, as seen for tau which is poorly modified in 
vitro30-32. These observations suggest that some protein substrates 
are likely constitutively modified at physiological UDP-GlcNAc 
concentrations whereas modification of others, such as tau, varies 
depending on the cellular UDP-GlcNAc concentration30. Two 30 
other isoforms of OGT have been shown to arise by alternative 
splicing: a shorter mitochondrial isoform (mOGT) as well as the 
shortest form of OGT (sOGT)33, 34. The exact significance of 
these two shorter forms of OGT remains little explored, however, 
these enzymes lack some of the tetratricopeptide repeat (TPR) 35 
sequences that are situated to the C-terminal region of the enzyme 
relative to the catalytic units. The structure of OGT has been 
solved35 and previous proposals36-38 that the TPR domain would 
serve to bind and direct some substrates into the 
glycosyltransferase active site have recently received clear 40 
structural support for one protein substrate39. Given recent 
proteomic data, and in light of the structure of OGT, it appears 
that this enzyme predominantly modifies disordered regions of 
proteins. Quite remarkably, this enzyme has been shown to 
cleave one binding partner that is a substrate for glycosylation 45 
through a mechanism dependent on glycosylation. Given that the 
TPRs appear critical for binding proteins OGT likely participates 
in protein complexes and binds partners through this domain. 
Much remains to be learned about how OGT substrate specificity 
might be defined at the cellular and biochemical levels. 50 
1.3. O-GlcNAcase (OGA) 
Like the ogt gene, the human O-GlcNAcase (OGA) gene, 
originally named MGEA5, has also been cloned and is located on 
chromosome 1016, 40. The MGEA5 gene gives rise to an enzyme 
that is 916 amino acids in length. Both the optimal pH for this 55 
enzyme and the substrate specificity were deduced and indicate 
that OGA is a β-N-acetylglucosaminidase with a neutral pH 
optimum16, which is the same as the enzyme that was termed 
HexC and partly characterized much earlier after biochemically 
purification41. Two different isoforms of OGA have been 60 
described; a smaller isoform referred to as the nuclear variant of 
OGA (nvOGA or OGA-S), which arises by alternative splicing 
and contains only 662 amino acids42. The nuclear variant of OGA 
bears this name due to the nuclear localization of this isoform, 
whereas the full length protein (OGA-L) shows both nuclear and 65 
cytosolic localization42, 43. Both OGA-L and the OGA-S contain 
the core β-N-acetylglucosaminidase domain but differ in that 
OGA-S does not contain the inactive acetyltransferase-like 
domain found within the full length protein42. The catalytic 
mechanism of OGA is established and it is known that OGA 70 
recognizes predominantly the GlcNAc moiety of its substrates30. 
Enzymatic characterization of both OGA-L and OGA-S reveals 
that OGA-S is significantly less active than OGA-L with respect 
to the hydrolysis of O-GlcNAc44. Within brain tissue, the short 
isoform appears to only be expressed during development of the 75 
embryo45. Earlier biochemical studies reported several binding 
partners but these observations have not been pursued. 
1.4 Inhibitors 
To study the roles that O-GlcNAc plays within cells and 
organisms two general approaches have been used: genetic 80 
approaches and chemical approaches. Overexpression as well as 
knock-down of both OGA and OGT has been performed in a 
number of different systems46-51. Notably, as mentioned above, 
the conditional knock-out of OGT within neurons of mice leads 
to neuronal death and tau hyperphosphorylation29. Dramatically 85 
altering the levels of these proteins, however, may have effects 
independent of O-GlcNAc since both of these large multi-domain 
proteins have been shown to interact with several protein partners 
including those involved in regulating gene expression. For this 
reason, chemical approaches offer some benefit in that they do 90 
not directly modify the amount of the target protein present in 
cells, yet they are able to significantly reduce the activity of the 
target in cells and in vivo. Interestingly, it has been shown the 
inhibitors of OGA and OGT lead to modest changes in the 
expression levels of these proteins, highlighting the presence of a 95 
cellular homeostatic system that is likely working to try to 
maintain balanced O-GlcNAc levels. The other major advantage 
of chemical approaches is that the chemical agent can be 
withdrawn and the system allowed to return to an unperturbed 
state. 100 
 A small number of OGT inhibitors having some activity in 
cells have been described52-54. Among these are some, discovered 
through high-throughput screening, that are able to inactivate 
OGT within cells. These show modest efficiency at decreasing O-
GlcNAc levels and likely hit other cellular targets. A different 105 
approach has been to use an acetylated GlcNAc analogue, 2-
acetamido-2-deoxy-5-thio-D-glucosamine, which can be 
converted by cells to form UDP-5SGlcNAc, which then inhibits 
OGT and also modestly lowers the cellular concentration of 
UDP-GlcNAc55. This compound shows a Ki value of about 8 µM110 
for human OGT and an EC50 value of between 0.5 and 5 µM for 
decreasing O-GlcNAc levels in cultured cells55. Further work in 
the area of OGT inhibitors is sorely needed.  
 In contrast to the case for OGT, a number of good OGA 
inhibitors have been uncovered. The first inhibitors of OGA to be 115 
described were PUGNAc and LOGNAc, which were shown to be 
inhibitors of a different β-N-acetylhexosaminidase56. PUGNAc 
was later found to also potently inhibit OGA (KI = 20 nM)
15, 57, 58
but was later shown to equally well inhibit human lysosomal 
hexosaminidase B58. Another early tool was streptozotocin, a 5 
GlcNAc analogue, which is a weak OGA inhibitor (KI = 2 mM)
59,
which, when coupled to its well characterized toxicity and the 
availability of better reagents, makes it an inappropriate tool to 
study O-GlcNAc60-62. A known compound63, NAG-thiazoline, 
resembles the enzyme intermediate found in the reaction 10 
mechanism of OGA and is a potent inhibitor but one that also 
inhibits the functionally related β-hexosaminidases58. Adding a 
pendant alkyl chain to the thiazoline ring resulted in inhibitors 
having good selectivity for human OGA over functionally related 
lysosomal β-hexosaminidases. These compounds exploit an 15 
extended pocket within the active site of OGA and one of the 
compounds derived from this study is NButGT, which is 
relatively potent (Ki = 600 nM) and 800-fold selective for OGA 
over the lysosomal β-hexosaminidases. This selectivity is 
manifested both in vitro but also in vivo, where it acts to increase 20 
O-GlcNAc but does not affect ganglioside levels. The same
approach to selectively was pursued by Van Aalten and co-
workers to take a known compound to generate the potent and
selective inhibitor GlcNAcstatin64. These GlcNAcstatins have not
yet been used in vivo, perhaps owing to the difficulty in 25 
synthesizing large amounts. Rational modification of NButGT 
gave rise to the compound Thiamet-G, which differs from 
NButGT only by replacement of a methylene unit with an amine 
functionality. Thiamet-G is highly potent (Ki = 20 nM), highly 
selective (37,000-fold) for human OGA, and is remarkably stable 30 
in solution. In addition, thiamet-G is also able to cross the blood-
brain barrier. All of these properties thus make thiamet-G useful 
for in vivo experiments. Indeed, Thiamet-G is now commercially 
available from several vendors and has been used in over a dozen 
different studies since its first description including several in 35 
mice65-71. 
1.5. The HBSP: Biosynthesis of UDP-GlcNAc 
As mentioned above, OGT is a bisubstrate enzyme requiring two 
different substrates: a protein substrate and the donor sugar UDP-
GlcNAc. UDP-GlcNAc is involved in central metabolism and is 40 
also used as a substrate by a number of other GlcNAc 
transferases. UDP-GlcNAc can be synthesized from glucose by 
the serial action of five different enzymes within a biosynthetic 
pathway that is referred to as the hexosamine biosynthetic 
pathway72 (HBSP) (See Figure 2). Glucose, upon entry into the 45 
cell, is phosphorylated by hexokinase at the 6-hydroxyl and is 
then isomerized, by phosphoglucose isomerise, to fructose-6-
phosphate73, 74. The action of glutamine fructose-6-phosphate 
transaminase (GFAT) then converts fructose-6-phosphate to 
glucosamine-6-phosphate in what is the rate limiting step for the 50 
HBSP75. This transformation involves the transamination of the 
amine functionality of glutamine to the carbonyl group of 
fructose-6-phosphate, followed by isomerisation to generate 
glucosamine-6-phosphate72. The acetyl group is then installed by 
glucosamine-6-phosphate acetyltransferase76 (GNAT) to form N-55 
acetylglucosamine-6-phophate (GlcNAc-6-phosphate) followed 
by another isomerisation involving phosphorylation of the 
anomeric hydroxyl group and dephosphorylation of the 6-
hydroxyl group the enzyme by N-acetylglucosamine 
phosphoglucomutase77 (AGM) to produce N-acetylglucosamine-60 
1-phosphate (GlcNAc-1-phosphate). Finally, in the last step, N-
acetylglucosamine-1-phosphate pyrophosphorylase (AGX)
catalyzes the transfer of uridine-5’-diphosphate from UTP to N-
acetylglucosamine 1-phosphate to form UDP-GlcNAc78.
Additionally, both glucosamine and N-acetylglucosamine can 65 
also enter into the HBSP via so-called ‘salvage’ pathways. In 
these cases, glucosamine or N-acetyglucosamine are 
phosphorylated by their respective kinases, to yield glucosamine-
1-phosphate or N-acetylglucosamine-1-phosphate, which are both
HBSP intermediates79, 80 (Figure 2).70 
1.6 Metabolic control of O-GlcNAc levels 
As shown above in Figure 2, between 2-3% of all glucose that 
enters the cell is shunted down the HBSP72. Because UDP-
GlcNAc is made from dietary glucose, the HBSP has been 
proposed as a nutrient sensing pathway and indeed, studies have 75 
shown that UDP-GlcNAc levels vary with glucose availability81,
82. Though UDP-GlcNAc itself is a feedback inhibitor of the 
HBSP, flux through this pathway can be increased by providing 
cells exogenous nutrients including lipids, uridine, or 
glucosamine81, as well as by inducing various cellular stresses83, 80 
which all lead to increased O-GlcNAc levels. 
 Multiple papers have shown in adipocytes that increased flux 
through the HBSP can lead to the development of insulin 
Figure 2. The Hexosamine biosynthetic pathway. UDP-GlcNAc 
is produced by the hexosamine biosynthetic pathway (HBSP) 
from cellular glucose via the action of two enzymes from central 
metabolism (hexokinase and phosphoglucose isomerase) and the
four enzymes which make up the HBSP (GFAT, GNAT, AGM 
and AGX).  
resistance84, 85. Based on these results it was proposed that O-
GlcNAc may act as a nutrient sensor because OGT catalyzed O-
GlcNAcylation of some proteins depends on the concentration of 
UDP-GlcNAc86. In times of hyperglycemia, UDP-GlcNAc levels 
should be increased and thus lead to increased O-GlcNAc levels, 5 
which has been reproducibly shown87, 88. Thus increased O-
GlcNAc levels could act to sense nutrient availability and studies 
using both chemical and genetic approaches have supported this 
view. First, using a chemical approach, treatment of 3T3-L1 
adipocytes with the OGA inhibitor, PUGNAc, was shown to 10 
result in increased O-GlcNAc levels and result in impaired 
glucose uptake and insulin resistance in these cells89. Other data 
using different inhibitors, however, has not replicated these 
findings regarding glucose uptake or insulin resistance neither in 
3T3-L1 adipocytes, nor in rats or diabetic mice90-92. The 15 
mechanism by which PUGNAc acts in this regard therefore 
remains unclear, though it is known to have some off-target 
effects93, 94. Overexpression of OGT in muscle and fat cells51 as 
well as in the liver50 resulted in insulin resistance and perturbed 
glucose homeostasis, respectively. Finally, with respect to the 20 
brain, starvation of mice, and thus decreased glucose availability, 
results in dramatically lower levels of O-GlcNAc in the brain95. 
Collectively, these studies show that O-GlcNAc fluctuates in 
response to glucose availability and suggest that such fluctuations 
may act to sense glucose availability. The discrepancy in results 25 
between the use of genetic methods and inhibitors suggests there 
may be differences in these approaches, as suggested in an earlier 
section of this review. Whether these changes in O-GlcNAc 
levels, seen under hypo- or hyperglycemic conditions, serve a 
functional role in adaptation to nutrient excess or deprivation or, 30 
instead, whether they might have deleterious effects such as 
inducing insulin resistance, remains a question of interest. 
Reconciling the differences observed when using genetic and 
chemical methods could yield valuable insights into the 
mechanisms by which the O-GlcNAc system may modulate 35 
cellular signalling. 
1.6 Biochemical effects of O-GlcNAc on proteins 
Study into the biophysical effects of glycosylation on proteins has 
been a longstanding topic, though the majority of studies have 
focused on cell surface glycosylation. Studies into N-glycans, 40 
which have at their core a GlcNAc residue β-linked to the amide 
nitrogen side chain of asparagines, have proposed that N-
glycosylation assists proteins in achieving their specific folds96, 
increases the structural rigiditity of proteins97 and increases 
resistance to thermal unfolding and aggregation98, 99. The size and 45 
complexity of N-glycans, which comprise more than eight 
carbohydrate residues, is significantly greater than for the O-
GlcNAc modification. However, it has been established that 
simply the presence of the first N-linked GlcNAc residue 
accounts for the resistance to thermal unfolding that is seen for 50 
RNAseB. Indeed, elongation to a more complex glycan does not 
further enhance the protection afforded by just one residue 
against thermal unfolding98. More recent evidence suggest that 
the single GlcNAc in an N-glycan might be able to stabilize 
proteins through carbohydrate-π  interactions with the nearby 55 
protein sidechains100. 
By analogy to N-glycans, it is possible that a basic biochemical 
role for O-GlcNAc may be to stabilize proteins to prevent them 
from unfolding or aggregating. Notably, O-GlcNAc is found most 
abundantly on disordered regions of proteins, which is consistent 60 
with a potential protective role since it is fairly well established 
that proteins containing large intrinsically disordered regions are 
particularly susceptible to misfolding to form aggregates. A few 
studies have provided some suggestive evidence supporting the 
idea that O-GlcNAc may offer protection against protein 65 
aggregation. First, overexpression of OGT in Chinese hamster 
ovary (CHO) cells was suggested to result in less protein 
aggregation in cells following incubation at 45 °C101. Second, 
overexpression of OGA to reduce O-GlcNAc levels appeared to 
reduce the thermal stability of Sp1 in cells102. Finally, O-GlcNAc 70 
has been shown to increase the solubility of keratins103. In 
addition to these suggestive findings, O-GlcNAc has been shown 
using nuclear magnetic resonance (NMR) studies to alter the 
conformation of the N-terminus of the murine estrogen 
receptor104. More direct biochemical data has shown that O-75 
GlcNAc modification of TAB1 decreases its thermally induced 
aggregation and O-GlcNAc has also been shown to influence tau 
aggregation as will be further discussed below71.  
1.7 Effects of O-GlcNAc on other PTMs 
The O-GlcNAc modification has drawn parallels to serine / 80 
threonine (Ser/Thr)  phosphorylation because both of these 
modifications are dynamic and can be added or removed multiple 
times during the lifespan of a particular protein18. In a few cases 
O-GlcNAc has been found to be reciprocal to Ser/Thr
phosphorylation105, 106. O-GlcNAc site-mapping studies on85 
proteins which are both O-GlcNAc modified and phoshorylated
indicates that O-GlcNAc sites sometimes occur near
phosphorylation sites, although this is not universally the case.
Proteomics studies using OGA inhibitors have shown that
pharmacologically increased O-GlcNAc levels lead to changes in 90 
protein phosphorylation. For these reasons it has been 
hypothesized that O-GlcNAc and phosphorylation can compete 
for the same Ser/Thr residues and can thus exist in a dynamic 
equilibrium as shown in Figure 3.  
 However, recent large scale proteomic analysis showed that O-95 
GlcNAc and Ser/Thr phosphorylation were not coincident more 
than would be expected by chance27.  On the basis of these 
observations, it appears unlikely that O-GlcNAc serves in a 
widespread manner to antagonize protein phosphorylation for 
regulatory purposes. However, such direct or proximal 100 
competition is likely to occur in specific instances, as seen for 
CK2107 and CamKIV108. Given these more recent large scale site 
Figure 3. O-GlcNAc can be reciprocal to phosphorylation. The 
existence of serine or threonine residues that are known to be 
both phosphorylated and O-GlcNAc modified dictates that such 
residues can exist in one of three different states; 
phosphorylated, glycosylated, or free hydroxyl. The formation of 
these states is regulated by the appropriate enzymes. Direct 
competition for the same serine or threonine residues or sites 
nearby could result in a dynamic equilibrium between these three 
states. 
mapping studies, the possible relationship between O-GlcNAc 
and phosphorylation might be more likely to stem from an 
indirect mechanism where O-GlcNAc modification of kinases or 
phosphatases could alter the activity of these enzymes. Notably in 
this regard, it has been observed, through large scale proteomics 5 
studies as well as targeted studies on specific proteins, that 
decreases in protein phosphorylation can be induced by acute 
administration of OGA inhibitors70, 109-111 but that longer term 
treatment with inhibitors does not influence phosphorylation on 
proteins such as tau67, 69, 70. This transient effect suggests O-10 
GlcNAc may influence the activity of kinases and phosphatases 
in the short term but that such changes diminish over time, 
perhaps because the cell gradually adapts to sustained changes in 
global O-GlcNAc levels.  
 Beyond its interaction with phosphorylation, O-GlcNAcylation 15 
has also been shown to have cross-talk with other post-
translational modifications. One such example of this is the 
interaction of O-GlcNAcylation and ubiqutinylation. For 
example, the O-GlcNAcylation of histone H2B appears to 
facilitate its monoubiquitination112 and decreased global 20 
ubiquitination was observed upon either glucosamine or 
PUGNAc treatment113. More recently, it has been suggested that 
O-GlcNAc impairs ubiquitination of other proteins such as β-
catenin, perhaps through direct competition. Further research is
needed to better understand the relationships between O-GlcNAc 25 
and ubiquitin as well as other post-translational modifications. 
2. Alzheimer’s Disease (AD)
Alzheimer’s Disease (AD) was first described in 1906 by a 
German physician, Alois Alzheimer, after he evaluated the 
clinical symptoms and the subsequent autopsy results of one of 30 
his patients, Auguste D.114, 115. In the years since its first 
description, AD has been revealed as a progressive 
neurodegenerative disorder that affects memory and learning. 
The most important known risk factor for the development of AD 
is age116, however, type II diabetes is also a major risk factor as 35 
will be discussed further below. AD can be subdivided into two 
different subtypes categorized by the age at onset: early onset AD 
(EOAD) and late onset or sporadic AD (LOAD)117. EOAD 
accounts for about 1-6% of all cases of AD and typically 
develops between 30-60 years of age117. LOAD, however, is the 40 
most common form of the disease and is defined by an average 
age of onset of 60-65 years age or later117. A family history of 
AD can occur in people who are diagnosed with either EOAD or 
LOAD. However, a far higher fraction, 50-60%, of all EOAD 
patients have disease that can be attributed to a familial origin118, 45 
119. Due to the increasing incidence of LOAD (hereafter referred 
to as AD), and the associated societal burden, extensive research 
in the AD field is being directed at identifying potential disease 
modifying therapeutic strategies. A critical step in the process of 
identifying disease modifying therapeutics for AD is 50 
understanding the pathological features of the disease, how they 
arise, and how they progress.  
 When Alzheimer first presented the case of Auguste D. he 
described the presence of evenly distributed atrophy in the 
brain114, 115, which is the most obvious late stage feature of AD. 55 
Upon silver staining of brain sections from Auguste D. Alzheimer 
described two distinct pathologies. The first of these was the 
presence of ‘tangles’ of neurofibrills, which he correctly 
identified as being intracellular. In the cerebral cortex, Alzhiemer 
described the second pathology as being “minute miliary foci 60 
which are caused by the deposition of a special substance in the 
cortex”114, 115. Today, we know that these ‘tangles’ of 
neurofibrills are indeed intracellular tangles made up of a 
microtubule-associated protein called tau and that the “minute 
miliary foci” are neuritic plaques caused by the deposition of 65 
Alzheimer’s “special substance” which has been revealed to be 
peptides cleaved from the amyloid precursor protein.  
2.1 O-GlcNAc in AD – The link between AD-related 
pathology and impaired glucose uptake/metabolism. 70 
Major strides have been made in understanding the temporal 
relationship between the two main pathologies in AD. Among the 
most notable recent achievements comes from the Alzheimer 
disease neuroimaging initiative (ADNI), which is a private-public 
consortium of basic scientists and clinicians aiming to find better 75 
ways to detect AD as well as evaluate the progression of AD over 
time using imaging modalities and biomarkers. This work 
involves longitudinally following a cohort of patients over years, 
who display dementia characteristic of AD, those having early 
dementia referred to as mild-cognitive impairment (MCI), those 80 
who suffer from subtle memory complaints, and those who are 
cognitively normal and healthy who function as a control 
group120, 121. Based on this longitudinal data changes in AD 
clinical parameters and biomarkers can be tracked within 
individual patients. Already evident from these ongoing studies is 85 
the fact that the earliest changes in AD are the presence of 
amyloid-β peptides in the cerebrospinal fluid that parallel the 
formation of amyloid plaques120, 121. Subsequently, impairments 
in glucose metabolism are seen and this is followed by the 
appearance of tau within the CSF. Finally, changes in cognitive 90 
performance appear after these changes in CSF biomarkers120, 121. 
Two points are particularly salient to this review. First, ADNI 
data indicates aberrant glucose metabolism follows amyloid 
pathology and precedes tau pathology. Positron emission 
tomography studies using 2-fluoro-2-deoxy-glucopyranose 95 
support these ADNI data, showing that cerebral glucose 
metabolism declines progressively with normal aging and 
becomes further impaired in AD122-124. Conversion from MCI to 
AD also tracks significantly with the degree of impairments in 
glucose metabolism125-127 . Biochemical evidence suggests that 100 
insulin and insulin receptor levels decrease within normal aging 
brain while levels of insulin receptors remain higher in 
concentration within AD brain as compared to age-matched 
controls128 which may be a compensatory mechanism working to 
counteract impairments in glucose utilization. The major neuronal 105 
glucose transporter, GLUT3, has been shown to be decreased in 
AD brain129 and its translocation to the plasma membrane is 
reported to result from the action of insulin130 as well as by 
depolarization of the membrane131. Therefore, the loss of synaptic 
connections within AD brain associated with neuronal death132 110 
may thus explain the decreased expression or translocation of the 
GLUT3 and resulting impairments in glucose utilization.  Second, 
glucose metabolism becomes impaired prior to tau becoming 
detectable in the CSF. Although this data is correlative, it is 
consistent with a scenario in which impaired glucose metabolism 115 
may be a factor contributing to tau pathology. 
 In addition to human data focused on AD pathology, studies of 
various transgenic mouse models of AD have also shown 
impairments in glucose metabolism occur within the brain133-138. 
This work is important because it suggests that impaired glucose 5 
metabolism can arise from toxic gain of function of these proteins 
and is not simply a confounding symptom in AD patients. 
Notably, Type II diabetes mellitus (T2DM) is a major risk factor 
for AD139, 140 and various mechanisms have been proposed to 
account for this observation (see for example141-143). However, 10 
because insulin resistance leads to decreased cellular glucose 
uptake and can influence levels of cell surface glucose 
transporters, T2DM can lead to impaired brain glucose 
utilization. Indeed, high blood glucose levels have been found in 
humans to correlate with glucose hypometabolism in regions 15 
susceptible to neurodegeneration in AD144, 145. Consistent with 
these observations in humans, it has also been found that diet-
induced insulin resistance in animal models146, including 
transgenic AD models147-149, exacerbates AD pathologies. These 
findings suggest that impaired brain glucose metabolism is both 20 
driven by and exacerbated AD pathologies. These data also 
suggest that early maintenance of glucohomeostasis by lifestyle 
changes or therapeutic intervention may protect against AD. 
 On balance, the data described above point to impairments in 
glucose metabolism and utilization being a central feature of AD. 25 
The deleterious effects of T2DM as well as toxic tau and Aβ 
species on brain glucose utilization likely contributes to severity 
of AD pathologies. Mechanistically, however, the processes by 
which impaired glucose utilization drives these pathologies in the 
brain remains unclear. We believe the current data is pointing to 30 
O-GlcNAc being one factor linking impairments in glucose
metabolism with these hallmark pathologies in AD. Because
UDP-GlcNAc is derived from glucose via the hexosamine
biosynthetic pathway, these early impairments in glucose
utilization in the AD brain should lead to lower levels of UDP-35 
GlcNAc and thus lower levels of O-GlcNAc modified proteins. 
This appealing hypothesis has been supported through studies in 
which brain tissue from AD patients were found to have lower O-
GlcNAc levels when considering post-mortem delay110 and more 
recently in a different patient population where decreased overall 40 
cytosolic O-GlcNAc levels were observed in frontal cortex but 
not cerebellum150. An earlier study using different analytic tools 
also observed no change in O-GlcNAc levels within the cytosolic 
fraction but did see increased O-GlcNAc levels within the 
detergent insoluble fraction of AD brain tissue from several 45 
regions other than cerebellum151. 
If the O-GlcNAc modification plays a protective role by 
limiting Aβ and tau toxicity in the brain then decreased glucose 
utilization and consequent lower O-GlcNAc levels could 
represent a failure of this protective mechanism. Such a 50 
molecular link could offer one mechanism by which T2DM and 
impaired brain glucose utilization drives AD pathologies. 
3. Alzheimer’s Disease (AD): O-GlcNAc and
amyloid-β
The “special substance” contained within the “minute miliary 55 
foci” that Alzheimer described was first isolated in 1984152. 
Glenner and Wong purified a 4500 Da peptide from neuritic 
plaques, which they speculated was a product arising from 
cleavage of a larger serum protein152. This peptide, initially 
referred to as the A4 peptide, was later purified from neuritic 60 
plaques and was shown to form higher order aggregates that 
assemble into and are the major constituent of plaques153. Not 
long after, the gene encoding the A4 peptide (found on 
chromosome 21154) was cloned and shown to encode a protein of 
695 amino acids resembling a cell surface receptor155. This 65 
protein was named the amyloid precursor protein (APP) and the 
A4 peptide derived from it was renamed the amyloid-β peptide. 
APP is a member of the conserved type I transmembrane proteins 
that are found across a number of species and orthologs are found 
in Caenorhabditis elegans156, Drosophila Melanogaster157, Danio 70 
Rerio (zebrafish)158 and Xenopus Laevis159. APP has a large 
extracellular domain and can exist as one of three different 
isoforms that are 695, 751, or 770 amino acids in length160. These 
species are generated by alternative splicing and the 695 amino 
acid form of APP is primarily expressed in the brain whereas the 75 
751 and 770 amino acid isoforms are expressed in other 
tissues161. 
Since the discovery of the amyloid-β peptide and the 
realization that it is produced from the larger APP, many studies 
have aimed to address how the amyloid-β peptide is generated 80 
from the precursor protein. It has emerged that APP is processed 
by three different proteases: α162, β163, and a γ 164, 165 secretase 
complex, for which the complete set of protein components are 
still being identified (see Figure 4). The cleavage of APP by α-
secretase within the extracellular domain of APP gives rise to 85 
what is referred to as either the non-amyloidogenic166, whereas 
cleavage within this domain by β-secretase results in processing 
within what is termed the amyloidogenic pathway167, 168. 
Cleavage by α-secretase within the extracellular domain liberates 
most of the extracellular domain, which is referred to as sAPPα, a 90 
soluble fragment, and the C-terminal fragment, APP-CTFα, 
which remains bound in the membrane162. Further cleavage of 
APP-CTFα within the transmembrane region by the γ-secretase 
complex results in the formation of the non-amyloidogenic 
product, p3, and the APP intracellular domain, AICD166. 95 
Conversely, cleavage by β-secretase within the extracellular 
domain gives rise to the soluble sAPPβ fragment and the 
membrane bound portion, APP-CTFβ163. Cleavage of the APP-
CTFβ fragment within the transmembrane region by the γ-
secretase complex gives rise to the amyloid-β peptide (either 40 100 
or 42 amino acids, Aβ40 or Aβ42) and the AICD167, 168. 
In 1991 a breakthrough occurred when it was discovered that a 
mutation in the APP gene can give rise to EOAD, which appears 
nearly identical to LOAD in terms of clinical onset and 
pathophysiology169. This advance was considered important 105 
because it allowed the formulation of what has become known as 
the ‘amyloid hypothesis’ or the ‘amyloid cascade hypothesis’170. 
The central idea behind the amyloid hypothesis is that the 
production of the amyloid-β peptide is sufficient to commence 
the pathological cascade which ultimately results in all of the 110 
pathological hallmarks of AD, including the amyloid plaques and 
the neurofibrillary tangles composed of tau. Implicit in this 
hypothesis is that the development of neurofibrillary tangles are 
downstream of plaque formation and this idea is now quite well 
supported by the accumulating ADNI data120, 121. 115 
 A great deal of attention has been focused on the post-
translational modification of APP and proteins that process APP 
(for review see1, 2). With regard to O-GlcNAc, APP was first 
suggested to be modified by Griffith et al., who used both 5 
antibody detection and 3H-galactosyltransferase labelling to 
indentify the presence of an O-linked GlcNAc residue171. Further 
to this, Jacobsen et al. have also used antibody binding to suggest 
that APP is O-GlcNAc modified but they further showed that 
increased O-GlcNAc leads to decreases in the Aβ40 amyloid-β 10 
peptide being released from cultured SH-SY5Y cells172. This 
work, however, made use of the non-selective OGA inhibitor 
PUGNAc, and thus should be interpreted with some caution. 
Very recently, however, Kim and co-workers described the long-
term treatment of an AD mouse model of amyloid-β deposition 15 
(5xFAD mice) with the selective OGA inhibitor NButGT173. 
These investigators saw significant reductions in the number of 
amyloid plaques, the amount of the amyloidogenic Aβ40 and 
Aβ42 peptides, and a significant prevention of cognitive 
impairment173. Additionally, these investigators attempted to 20 
explain these in vivo effects of NBuGT treatment by treating 
Chinese hamster ovary (CHO) cells expressing the Swedish 
mutation in APP, which results in substantially increased 
production of Aβ40 and Aβ42. In a dose dependent manner, it 
was shown that NButGT decreases the amount of the C-terminal 25 
fragment of APP (APP-CTF). These effects were suggested to 
result from decreases in γ-secretase activity and, more 
specifically, due to O-GlcNAc modification of the nicastrin 
component of the γ-secretase complex173. It should be noted, 
however, that levels of Aβ40 and Aβ42 were not evaluated in this 30 
work and thus it is difficult to conclude if the in vitro effect on 
APP-CTF can explain the in vivo effects of NButGT. With the 
exception of mapping the O-GlcNAc of nicastrin to Serine-708, 
none of the above mentioned studies have described the 
unambiguous identification of O-GlcNAc modification sites on 35 
APP nor any other functionally involved proteins. Given the 
current data, it is difficult to speculate what roles, if any, O-
GlcNAc present on APP might serve in its normal biological 
function or in Alzheimer-type neurodegeneration. This area 
therefore merits closer attention from investigators to verify and 40 
extend these findings by identifying sites of O-GlcNAc 
modification, clarifying the effects of cellular O-GlcNAc on APP 
processing, and addressing the biological roles of O-GlcNAc on 
these proteins.  
4. Alzheimer’s Disease (AD): O-GlcNAc and tau45 
4.1 Discovery, Gene Structure, and Biochemical Function 
In 1975, the Kirschner group co-purified and characterized a 
protein from repeated cycles of polymerization of porcine brain 
tubulin174. This protein, which was capable of greatly accelerating 
tubulin polymerization in vitro was given the name “tau factor”. 50 
At that time one remarkable property of tau factor was 
immediately evident; tau could be boiled for 5 minutes and still 
maintain its tubulin polymerization activity in vitro. The human 
gene encoding microtubule associated protein tau (MAPT), as tau 
factor is now called, is located on the long arm of chromosome 55 
17175. Disruption of the MAPT gene results in mice that develop 
normally and are able to reproduce normally176. Recently, 
however, tau deficiency has been shown to cause Parkonsinism in 
aged mice177. The absence of a clear phenotypic effects until 
greater than 12 months of age is speculated to stem from the 60 
presence of various other functionally redundant microtubule 
associated proteins. Alternative splicing of tau in the human brain 
gives rise to six different isoforms which range in size from 352 
amino acids to 441 amino acids178. The isoforms differ in their 
inclusion or exclusion of three different exons; exon 2, exon 3 65 
and exon 10. Inclusion of exon 10 results in tau isoforms that 
contain four imperfect microtubule binding repeats (referred to as 
0N4R tau), whereas exclusion of exon 10 results in isoforms 
having three repeats (referred to as 0N3R tau)179. Inclusion of 
exon 2 results in one N-terminal insert to generate 1N3R and 70 
additional inclusion of exon 10 leads to 1N4R tau. Inclusion of 
exons 2 and 3 results in two N-terminal inserts in 2N3R and the 
presence of exon 10 leads to 2N4R tau179 (see Figure 5 for the 
depiction of the longest isoform of human tau (2N4R)). Within 
human brain roughly equal proportions of the 3R and 4R tau 75 
isoforms are expressed178 whereas rodent brain expresses 
primarily the 3R tau isoforms180. Interestingly, expression of tau 
protein in the human brain is developmentally regulated, with the 
Figure 4.  Proteolytic processing of the amyloid precursor protein 
(APP). Proteolytic processing of APP can proceed along one of 
two pathways depending on the action of three different 
proteases, α, β and γ-secretase. These two pathways generate 
either non-amyloidogenic products or amyloidogenic products. 
Upon β-secretase cleavage, the soluble APPsβ and the membrane 
bound APP-CTFβ fragments are generated. The APP-CTFβ can 
then be cut by γ-secretase to liberate the amyloidogenic amyloid-
β peptide and the APP intracellular domain (AICD). Upon α-
secretase cleavage, the soluble APPsα and the membrane bound 
APP-CTFα fragments are generated. The APP-CTFα can then be 
cut by γ-secretase to liberate the non-amyloidogenic p3 peptide 
and the AICD. 
3R isoforms predominating in the fetal human brain. Altered 
levels of tau isoform expression within the human brain is 
thought to play a role in dementia181 and the ability to alter 
isoform ratios is a topic of current interest.  
4.2 Tau Structural Characteristics 5 
As expected given the extreme stability of tau in solution, tau 
contains many hydrophilic amino acids and a paucity of 
hydrophobic amino acids. For example, the longest human 
isoform of tau (441 amino acids) contains 80 serine and threonine 
amino acids, no tryptophan residues, and only five tyrosine 10 
residues182. Given these features, it came as no major surprise that 
tau is a predominately unstructured and elastic protein183. 
Circular dichroism indicates that tau contains little secondary 
structure and behaves like a random coil184. Recent biophysical 
studies have supported the idea that tau may assume a general 15 
global conformation in solution that is more compact than a 
random coil185 and also suggested that a precursor to tau 
aggregation is its adoption of further compressed conformation 
that has been termed the “paperclip” conformation186, 187. 
4.3 Role in Alzheimer’s Disease 20 
Tau has been revealed to exist within the bovine brain in a non-
phosphorylated form as well as a phosphorylated form188. 
Phosphorylation of tau was shown to impair its ability to bind to 
and enhance microtubule polymerization189-192. This loss of 
function upon phosphorylation has deleterious consequences as 25 
tau is normally found almost exclusively within the axon of 
neurons193 where it stabilizes microtubules to allow efficient 
movement of cargo over long distances194. Indeed, some 
investigators believe that failures in axonal transport play a 
significant and early role in neurological disease195. The fact that 30 
phosphorylation impairs the ability of tau to bind microtubules 
implies that the normal regulatory function of tau 
phosphorylation may be to tune the affinity of this protein for 
microtubules and regulate its behaviour within the axon.  
 Tau shot to the forefront of AD research in the mid-1980’s 35 
when it was discovered to be the major component of 
neurofibrillary tangles by Grundke-Iqbal and coauthors196, 197. 
Neurofibrillary tangles had been previously shown to consist of 
so called paired-helical filaments (PHFs) because of the twisted 
pair appearance of these filaments seen by electron 40 
microscopy198-200. These PHFs can be conveniently enriched by 
exploiting their unique insolubility in a common detergent, N-
lauroylsacrosinate (sarkosyl)201. Antibodies raised against PHFs 
from AD brains were found to react with purified tau from bovine 
brain. Tau protein in the mammalian brain contains roughly 1.9 45 
moles of phosphate per mole of tau protein spread across ~10 
different sites202. During the course of Alzheimer disease, tau 
becomes hyperphosphorylated leading to an increase in the 
stoichiometry of phosphorylation to 2.6 and 6-8 moles of 
phosphate per mole of soluble AD brain tau and paired-helical 50 
filament tau, respectively, across ~45 different sites202. A general 
hypothesis for tau dysfunction is that tau hyperphosphorylation 
leads to detachment from microtubules thereby increasing the 
amount of unbound heavily phosphorylated tau which then 
aggregates to form paired-helical filaments, which ultimately give 55 
rise to the neurofibrillary tangles that are characteristic of AD. 
Because NFTs are such large structures found within the cell 
body of neurons it was initially presumed that NFTs are the toxic 
species responsible for tau-driven neurodegeneration. However, 
newer data has lead to revised thinking about this view. Using 60 
doxycycline inducible expression of transgenic mutant human tau 
that aggregates rapidly in the mouse brain the rapid formation of 
NFTs could be observed203. However, when transgene expression 
was halted, NFTs continued to grow even as neurodegeneration 
was blocked and memory improved203. This data implies that the 65 
formation of NFTs may serve to sequester toxic species of tau, 
which are likely soluble tau oligomers. Work by Le Corre et al., 
using a different transgenic tau mouse has shown that prevention 
of tau hyperphosphorylation does not block the formation of 
NFTs although it does block the onset of motor impairment and 70 
presumptive neuron loss204. This work is also consistent with the 
idea that the toxic tau species are low molecular weight 
oligomers. Interestingly, it also suggests that 
hyperphosphorylation is required in order to produce the toxic tau 
species but is not essential for NFT formation. Further support for 75 
the toxic tau species being a smaller oligomer comes from cell-
based studies which have shown that tau misfolding and oligomer 
formation can be propagated from the outside of cells to the 
inside of cells and can be transferred between cells by low 
molecular weight species205, 206. Further confirmation of this 80 
process has now also been achieved in vivo where it has been 
shown that tau pathology is propagated along synaptic circuits 
from one connected neuron to another in a prion-like manner.207 
4.4 NFTs and mechanism of their formation 
A clear correlation between the number of NFTs and the severity 85 
of clinical dementia in AD has been demonstrated and argues 
strongly for tau dysfunction playing a critical role in AD 
pathogenesis208. This data contrasts to the lack of a strong 
correlation between the number of amyloid plaques and disease 
severity in AD209. For this reason, it is imperative to understand 90 
how NFTs arise in the AD brain since doing so could improve 
our understanding of the processes that ultimately lead to 
neuronal cell death and, by extension, enable the development of 
approaches that might block disease progression. Following the 
cloning of the MAPT gene, recombinant techniques made it 95 
possible to produce tau isoforms recombinantly within E.coli. 
Notably, recombinant tau on its own could not aggregate 
efficiently even at very high concentrations210. This observation 
suggested that hyperphosphorylation of tau is necessary to drive 
oligomer and PHF formation. Indeed, Alonso et al., have shown 100 
that phosphorylated tau from AD brain can easily assemble into 
authentic PHFs/NFTs whereas enzymatic dephosphorylation of 
this tau completely blocks its ability to aggregate211. Aggregation 
of recombinant tau, however, has been achieved in vitro without 
the need for tau phosphorylation by the inclusion of polyanions 105 
(such as heparin)212 or fatty acids (such as arachidonic acid)213 
within aggregation reactions. The general rationale for why 
Figure 5: The longest human isoform of tau and the locations of 
serine/threonines which have been shown to be O-GlcNAc 
modified. 
phosphorylation is thought to be due to this negatively charged 
modification decreasing the pI of tau, which leads to it being less 
positively charged at physiological pH values and therefore better 
able to self associate214. The presence of polyanions presumably 
acts in a similar manner, but in trans, to screen the positive 5 
charges of tau and render the tau-anion complex less positively 
charged. 
4.5 Tau and the O-GlcNAc modification 
Tau was first shown to be modified through studies by Arnold 
and Hart, who found bovine tau is extensively modified by O-10 
GlcNAc with an average stoichiometry proposed to be greater 
than four moles of GlcNAc per mole of tau protein215. Even at 
that time, it was noted that the presence of O-GlcNAc on tau 
protein might play a role in regulating the function of tau or 
perhaps the degree to which it can be phosphorylated215. Multiple 15 
different studies have lead to the observation that phosphorylation 
and O-GlcNAc on tau show some reciprocity. Several early 
independent studies have made use of both chemical and genetic 
approaches to note this reciprocal relationship. Gong and 
coworkers described a series of elegant studies that suggested that 20 
the addition of O-GlcNAc regulates the extent to which tau is 
phosphorylated in vitro in tissue culture cells and ex vivo in rat 
brain slices110. These authors demonstrated that when PC12 cells 
over expressing human tau are treated with the OGA inhibitor 
PUGNAc, which increases O-GlcNAc levels,56 there is a 25 
significant reduction in the extent of tau phosphorylation as 
measured using antibodies for several phosphoepitopes. These 
investigators also observed a similar phenomenon in rat brain 
slices studied ex vivo. Most notably, they found that cortex from 
AD brain showed lower levels of global O-GlcNAc, as compared 30 
to age and post-mortem delay matched brain, whereas O-GlcNAc 
levels in the cerebellum were unchanged. Suggestively, these 
authors also failed to detect O-GlcNAc on neurofibrillary tangles. 
Based on these collective findings, Gong and coworkers proposed 
that impaired glucose metabolism, which occurs early in disease 35 
progression in AD brain, would result in less UDP-GlcNAc 
production and consequently lower levels of O-GlcNAc on tau110. 
The net consequence of these potentially lower UDP-GlcNAc 
levels were suggested to be increased tau phosphorylation.  Since 
their first study, Gong and coworkers have shown that short term 40 
fasting of mice leads to decreased O-GlcNAc levels and increased 
tau phosphorylation95, lending support for this proposal regarding 
reciprocity. This reciprocal relationship was also observed 
independently by Lefebvre et al. who, using both 
galactosyltransferase labeling and wheat germ agglutinin, noted 45 
that more extensively phosphorylated tau had less O-GlcNAc. 
They also noted that by increasing tau phosphorylation using a 
protein phosphatase 1/2a inhibitor, okadaic acid, a corresponding 
decrease in tau O-GlcNAc levels could be induced109, 216. Finally, 
mouse genetics studies mentioned above, in which the gene 50 
encoding OGT was deleted specifically in neuronal tissue using 
the Cre-Lox system, revealed significantly increased 
phosphorylation of tau that was mirrored by a global decrease in 
O-GlcNAc levels29. More recently, the OGA inhibitor thiamet-
G70 was shown to increase global O-GlcNAc levels within brain.55 
Following acute treatment of mice with this compound, Yuzwa et
al. found that inhibitor treatment lowered tau phosphorylation at
several pathologically relevant sites including Thr-231, Ser-396, 
and Ser-42270 in a time dependent manner that was inversely 
related to the time dependent increases seen in global O-GlcNAc 60 
levels. 
 Other than observations regarding the reciprocal relationship 
between O-GlcNAc and phosphorylation on tau, little is known 
about the functional significance of tau O-GlcNAcylation. One 
reason for this lack of information is that the sites at which O-65 
GlcNAc is found on tau were unknown, making site-directed 
mutagenesis studies of limited utility. Using a bacterial co-
expression system Yuzwa et al. succeeded in mapping four O-
GlcNAc sites on tau at positions Thr-123, Ser-208, Ser400 and 
one of Ser-409, Ser-412, or Ser-41371, 217 (see Figure 5). One of 70 
these sites, Ser-400, was independently observed within both rat 
brain4 and the JNPL3 mouse model71. The Ser-208 and Ser-400 
sites have also been identified in vitro by NMR using 
recombinant OGT and tau peptides31. Further, Smet-Nocca, 
Lippens and coworkers used this site information to show that O-75 
GlcNAc at Ser-400 blocks priming phosphorylation by cyclin-
dependant kinase 2 (CDK2/cyclinA3) at Ser-400 and subsequent 
sequential phosphorylation by glycogen synthase kinase 3β 
(GSK3β) at Ser-400 and Ser-39631. These observations provide a 
molecular rational for how increased O-GlcNAc can lead to the 80 
decreased levels of phosphorylation at Ser-396 elicited in vivo by 
treatment of mice with thiamet-G70. 
 All of the studies described above have collectively shown that 
tau is O-GlcNAc modified at a number of different residues and 
that reciprocal modification by phosphorylation can occur over 85 
shorter times, such as observed upon acute dosing using OGA 
inhibitors. The potential impact of increased O-GlcNAc 
antagonizing tau phosphorylation has stimulated consideration of 
what the effect of sustained increases in O-GlcNAc levels would 
be on the formation and/or toxicity of hyperphosphorylated tau, 90 
which is of clear relevance in the various tauopathies including 
AD. Mutations in the MAPT gene are known to give rise to a 
group of diseases collectively referred to as frontotemporal 
dementia linked to chromosome-17  (FTDP-17); a progressive 
brain disorder that leads to impairments in behaviour, language, 95 
and movement218. Capitalizing on this knowledge, researchers 
have created transgenic mice expressing tau with some of the 
more common FTDP-17 mutations to produce tauopathy mice 
such as the JNPL3 mouse model219. JNPL3 mice express the 
0N4R isoform of P301L tau under the control of the mouse prion 100 
promoter. These mice develop robust tau hyperphosphorylation 
and neurofibrillary pathology in the spinal cord, brainstem, and 
the hindbrain but and less so in the forebrain. At roughly 6.5 
months of age these mice develop motor impairments leading to 
muscle atrophy and weight loss due to loss of motor neurons. 105 
Eventually, these mice loose a significant amount of body weight 
and become moribund. A number of other tau mouse models 
have since been produced carrying other FTDP-17 mutations 
including the Tg4510 mice, which carry the same P301L 
mutation but expressed under control of the tetracycline operator 110 
(tetO), which makes it possible to control expression of the 
mutant gene using doxycycline203. Other mouse models will not 
be described in detail here but readers are pointed to an excellent 
recent review220. 
 Recently, it was shown by Yuzwa et al. that long-term 
treatment of JNPL3 mice with thiamet-G71 leads to a prevention 
of neuron loss and a reduction in the number of NFTs in the 
brains of these animals71. Using a rabbit polyclonal antibody 
against O-GlcNAc at Ser-400 of tau in combination with mass 5 
spectrometry analysis of tau isolated from the brains of these 
mice, these authors showed that Ser-400 is indeed modified and 
that OGA inhibition resulted in increase tau O-GlcNAcylation at 
this residue. Within this study, it was found that long term 
inhibition did not lead to a reduction in tau phosphorylation nor a 10 
decrease in tau hyperphosphorylation, suggesting that decreased 
tau aggregation was hindered directly by O-GlcNAc 
modification71. These observations were further supported by in 
vitro studies showing that O-GlcNAc on recombinant 
aggregation-prone tau fragments inhibited their aggregation in 15 
vitro71. More recent data has found that increased O-GlcNAc 
modification of two other tau constructs, including the full length 
isoform, leads to decreased aggregation propensity while not 
affecting either the local or global conformation of tau32. This 
data suggests that O-GlcNAc on tau may play a protective role 20 
and thus the impairments in glucose utilization seen in AD brain 
may result in a failure of this protective function (Figure 6). 
Independent findings using thiamet-G in Tg4510 mice have just 
been reported and these closely support the findings of Yuzwa et 
al.71. A new monoclonal antibody directed toward O-GlcNAc at 25 
Ser-400 was used to show in Tg4510 mice that thiamet-G 
administration resulted in a 7-fold increase in tau O-
GlcNAcylation at this residue. OGA inhibition within the Tg4510 
model resulted in a similar decrease in NFT burden but it was 
also noted in this study that the levels of pathological 30 
hyperphosphorylated tau species were decreased but that the 
phosphorylation of non-pathological tau was unaffected. These 
observations are consistent with studies from the Gong group in 
which it was noted that tau aggregates were not O-GlcNAc 
modified110. The absence of an effect on tau phosphorylation 35 
upon chronic dosing with an OGA inhibitor is consistent with 
other reports in which OGA inhibitors have been used in mouse 
models for weeks to months67, 69, 71. In our opinion the Tg4510 
mouse model, which displays more uniform penetrance of tau 
pathology as compared to jnPL3 mice, is well suited to examine 40 
the detailed role of O-GlcNAc in the formation of tau pathology. 
This collective data indicates that chronic OGA inhibition leads 
to increases in tau O-GlcNAc modification at Ser-400, but also 
likely more widely at multiple modification sites. The data is now 
clear that these increases in tau O-GlcNAcylation lead to a lower 45 
aggregation propensity for tau, perhaps by a combined effect 
mediated by increasing the solubility of tau, destabilizing 
growing filaments, and antagonizing its pathological 
hyperphosphorylation.  
 The somewhat enigmatic observation that OGA inhibition 50 
affects tau phosphorylation when mice are acutely treated with 
inhibitors, yet not when animals are treated for weeks, may stem 
from multiple scenarios. One situation could be that these 
different post-translationally modified tau species are in relatively 
low abundance. Phosphorylation and O-GlcNAcylation may 55 
therefore be present on different pools of tau. Acute 
administration could then lead to effects on the activity of kinases 
and phosphatases, which the cell could adapt to over time. 
Alternatively, normal phosphorylation and pathological 
hyperphosphorylation may be of sufficiently high abundance 60 
such that phosphorylation could be antagonized by O-
GlcNAcylation, as suggested by Lippens and coworkers31. 
However, such a decrease in phosphorylation efficiency may be 
overcome in vivo through the sustained action of kinases that, 
overtime, enable normal levels of phosphorylation. In both cases, 65 
it appears likely that pathological hyperphosphorylation remains 
blocked. Blockade of pathological hyperphosphorylation may 
either be direct, or indirect and mediated by increased O-GlcNAc 
influencing other cellular processes. We believe it is indeed likely 
that the protective effects of O-GlcNAc are mediated through 70 
multiple mechanisms. To address these mechanisms new tools 
will be required to specifically detect O-GlcNAc on tau at various 
modification sites. Site specific monoclonal  and polyclonal 
antibodies that have been generated against tau O-GlcNAc 
modified tau, such as those developed against Ser-40066, 217, will 75 
be useful tools. The recent development of multiple reaction 
monitoring (MRM) strategies for the sensitive detection of O-
GlcNAc at specific sites of proteins from tissues71, 221 should 
similarly prove useful, particularly when used in conjunction with 
approaches for monitoring tau phosphorylation. Further 80 
mechanistic studies on the effects of O-GlcNAc in cells and in 
vivo are likely to shed light on these questions and in vitro studies 
on the effects of O-GlcNAc modification should also help clarify 
Figure 6. O-GlcNAcylation may play a protective role within the 
brain (Panel A) which becomes deficient in AD (Panel B).  
the processes at play. 
5. Potential role of O-GlcNAc in other
neurodegenerative disorders
In addition to the roles of O-GlcNAc on tau and APP in AD, a 
few studies have provided suggestive hints that O-GlcNAc may 5 
play a more general role in neurodegenerative disorders. First, 
Corbo et al. demonstrated that a pathological feature of 
amyotrophic lateral sclerosis (ALS) is the accumulation of axonal 
spheroids which are composed of neurofilament proteins (a type 
of intermediate filament)222. The light and medium chains of 10 
neurofilament proteins (NF-L and NF-M) are both O-GlcNAc 
modified as well as phosphorylated7, 223. Additionally, these two 
modifications appear, once again, to be reciprocal to one 
another224. Given that neurofilament phosphorylation has been 
suggested to precede their accumulation in axons225, these studies 15 
suggest that O-GlcNAc on neurofilament proteins may play a role 
similar to O-GlcNAc on tau as described above. In the context of 
ALS, Shan et al., have shown that O-GlcNAc levels are globally 
decreased in the spinal cord of mice carrying a mutation in super-
oxide dismutase 1 (SOD1)226. Familial mutations in SOD1 give 20 
rise to 20% of human cases of familial ALS227 . If O-GlcNAc 
provides a protective benefit, decreased O-GlcNAc in SOD 
mutation carriers might be a participating factor in ALS 
pathology. Interestingly, SOD16 and neurofilament proteins7 are 
all O-GlcNAc modified and all are found within protein 25 
aggregates in ALS. Accordingly, increased O-GlcNAc levels 
generated using OGA inhibitors could be a novel therapeutic 
strategy for ALS. Considering another aggregation prone protein 
implicated in neurodegenerative disease, O-GlcNAcylation sites 
have been identified on all of α, β and γ-synuclein4, 228. α-30 
synuclein is the principle component of Lewy Bodies in PD5 and 
mutations in this protein are linked to PD229. Recently, Marotta et 
al., have shown that an O-GlcNAc modified α-synuclein peptide 
does not aggregate in the presence of unmodified peptide230. This 
work suggests that O-GlcNAc may inhibit the aggregation of α-35 
synuclein in PD and a deficiency in O-GlcNAc, perhaps 
associated with aging, might contribute to this process. It is 
interesting in this regard that mutations in glucose transporter 1 
(Glut-1) have been linked to AD231, perhaps impaired glucose 
metabolism is a general features in neurodgenerateive diseases. 40 
Given the observations made for tau in AD models, perhaps 
increasing O-GlcNAc levels in PD thus might lead in an 
analogous manner to protective benefits in this disease by 
preventing the formation of toxic oligomers of α-synuclein. In a 
distinct vein, recent genetic studies in C. elegans showed that 45 
OGA and OGT null alleles affected the toxicity of two different 
length poly-glutamine (polyQ) expansions of the Huntingtin 
protein (Htn)232.  
 Collectively, these studies, when viewed in light of the role of 
O-GlcNAc in AD, suggests that O-GlcNAc may play a role in 50 
various neurodegenerative disorders involving protein 
aggregation. Indeed, Yuzwa et al71. have speculated that O-
GlcNAc modification may serve a general protective function by 
stabilizing proteins against aggregation. This concept is supported 
by observations regarding tau32, 71, α-syuclein230, and also for 55 
proteins that are not known to be involved in protein aggregation 
diseases such as TAB1, where it was found O-GlcNAc 
modification stabilized the protein against thermal aggregation71. 
Studies performed in cells have also suggested that increase O-
GlcNAc may decrease the aggregation propensity of proteins. 60 
Thus, therapeutic strategies aimed at modulating O-GlcNAc 
levels may hold significant promise for the treatment of these 
disorders. 
6. Perspectives and Conclusions
O-GlcNAc has attracted significant attention in recent years 65 
owing, in part, to the; (i) development of new tools that have 
enabled detection and manipulation of this modification within 
cells and in vivo233-235, (ii) the potential for interplay with protein 
phosphorylation was uncovered104, 106, 110, 236-238, (iii) clear 
connection to stress response emerged239 and, (iv) observation 70 
that OGT is an epigenetic regulator of gene expression240, 241. 
Knowledge regarding the functional roles of O-GlcNAc, 
however, remains in its infancy. As new tools, large datasets, and 
confirmatory studies become more common within the field, the 
principle functions of O-GlcNAc will doubtless become more 75 
clear. One notable study in this regard has been the large scale 
proteomic site mapping of O-GlcNAc and phosphorylation, 
which suggested that O-GlcNAc does not influence protein 
phosphorylation anymore than would be expected by chance27. 
This unexpected finding supports the idea that the effects on 80 
phosphorylation observed on altering O-GlcNAc levels in the 
short term may be a consequence of altered activity of kinases 
and phosphatases, which are themselves O-GlcNAc modified. 
The short term effects of increased O-GlcNAc on tau 
phosphorylation associated with OGA inhibition that sustained in 85 
mice treated for longer periods of time, suggests that cells are 
able to adapt to increased cellular O-GlcNAc levels to maintain 
homeostasis. This data, coupled with the absence of obvious toxic 
effects associated with treating rodents with OGA inhibitors for 
extended periods of time, suggests that O-GlcNAc may play a 90 
predominantly protective role within cells, a hypothesis that is 
consistent with early studies showing increased O-GlcNAc offers 
protection against a wide array of cellular stresses239.  
 With regard to the roles of O-GlcNAc in AD, the field is 
similarly at an early stage. The longstanding observations that 95 
diabetes is a risk factor for AD and contributes to impaired brain 
glucose metabolism, coupled with longitudinal studies showing 
glucose hypometabolism follows amyloid pathology but precedes 
tau pathology has stimulated interest in nutrient responsive 
changes within diseased brains. The link between AD and 100 
decreased O-GlcNAc levels described by Gong et al. opened the 
possibility that O-GlcNAc could be a contributing factor in AD. 
The demonstrated protective effects of inhibiting OGA in both 
tau and amyloid models, now replicated, have raised considerable 
interest in this approach as a therapeutic strategy to slow disease 105 
progression. Worthwhile to strengthen the protective benefits 
against tau-induced toxicity would be studies in tau mouse 
models harbouring different FTDP-17 mutations such as the 
R406W mutation. Likewise, it would also be of use to known if, 
when NFTs are allowed to form and the transgene is then 110 
repressed, does thiamet-G block further growth of NFTs. 
 While such studies are eventually likely to be published, the 
data has spurred interest in the basic mechanisms by which O-
GlcNAc acts to protect against these two pathologies since 
greater clarity in this area could lead to the development of useful 
targeted therapeutics as well as useful biomarkers for downstream 
clinical studies. The significant reduction in amyloidogenic Aβ40 
and Aβ42 observed by Kim et al173 suggests O-GlcNAc plays a 
significant role in APP processing. Even if O-GlcNAc does not 5 
act directly on APP, the study of how such large reductions in 
plaque load and Aβ40 and Aβ42 arise in this animal model will 
likely provide new insights into the pathogenesis of AD. O-
GlcNAc could, in theory, be involved in either the production of 
amyloid-β peptides or the clearance of amyloid-β or amyloid 10 
plaques. In order to distinguish between these two possibilities, 
investigators will need to thoroughly characterize amyloid-β 
production using cell models and approaches that allow the 
monitoring of clearance of proteins and peptides such as pulse-
chase experiments. In addition, to assess whether OGA inhibition 15 
leads to plaque clearance investigators could treat APP mutant 
mice with an OGA inhibitor after the appearance of plaques in 
the brain. Temporal control of mutant APP transgene expression 
could also be used to asses whether O-GlcNAc influences plaque 
clearance as OGA inhibitor treatment should yield more marked 20 
differences when mutant APP expression is shut off.  Similarly, 
the roles of specific O-GlcNAc modified residues on APP or APP 
processing proteins could be evaluated using site-directed 
mutagenesis. Much remains to be uncovered in this area of 
research. 25 
 While the role of O-GlcNAc on tau is somewhat clearer, many 
questions also remain. We have identified several O-GlcNAc 
modification sites on tau but perhaps more remain to be 
uncovered. We have also found that O-GlcNAc can antagonize 
tau phosphorylation in the short term but sustained increases in 30 
O-GlcNAc do not block normal tau phosphorylation. However,
increased O-GlcNAc does appear to prevent the formation of
pathologically hyperphosphorylated tau species and also blocks
the formation of NFTs in a mouse model. Finally, O-GlcNAc
modification of tau decreases its aggregation propensity in vitro. 35 
We do not understand, however, the stoichiometry of O-GlcNAc 
on tau in both healthy and diseased brain or whether it even 
matters if O-GlcNAc on tau is substoichiometric or 
stoichiometric. This depends in part on how O-GlcNAc 
modification of tau affects the pathological processes associated 40 
with tau toxicity. Nor do we have a good sense of how levels of 
O-GlcNAc change during normal aging and whether this
exacerbated in AD.  Similarly, we lack the tools to monitor O-
GlcNAc at all the sites known on tau and we lack knowledge of
how dynamic these sites are within human brain. Finally, are 45 
there other mechanisms by which O-GlcNAc acts to protect 
against tau toxicity, as these authors believe, or is the effect 
mediated solely through modification of tau. Answers to these 
and other questions will gradually unravel the roles played by O-
GlcNAc in neurodegenerative diseases. 50 
 In our opinion, with respect to the role of O-GlcNAc on tau in 
the AD brain, it would be of substantial value to the field to be 
able to monitor the longitudinal changes in the O-GlcNAc 
modification of tau with both advancing age and with advancing 
AD pathology. Because of the availability of both polyclonal and 55 
monoclonal O-GlcNAc tau antibodies we believe that these sorts 
of studies are now becoming a possibility. Investigators could use 
human brain tissue of differing ages as well as pathologically 
staged AD brain tissue to conduct this work. In addition, perhaps 
O-GlcNAc on tau could be detected in the cerebrospinal fluid of 60 
healthy controls and AD patients and used to monitor 
longitudinal change in these patients to see if there was  a 
correlation with disease progression. 
 The review of papers presented above presents a generally 
harmonious, yet admittedly incomplete, view of the literature. 65 
There are of course papers that do not readily fit within the 
proposed models. Specifically, studies making use of C. elegans 
as a model system for various neurodegenerative diseases 
indicates that suppression of OGT, with accordingly lower levels 
of O-GlcNAc, rescued the toxic phenotype associated with tau 70 
containing the V337M FTDP-17 mutation232 as well as Q40 and 
Q150 polyglutamine expansions of the Huntingtin protein. This 
observation is notable, since loss of OGT leads to decreased O-
GlcNAc whereas inhibition of OGA would lead to increased O-
GlcNAc. These results therefore argue against a protective role 75 
for O-GlcNAc as has been shown in other systems described 
above. The models examined are, however, quite different and 
loss of OGT is tolerated in C. elegans whereas in mammals it is 
essential for stem cell viability232. There may also be as yet 
unappreciated differences between using OGA inhibitors and 80 
genetic approaches involving knockout animal models. Very 
recently, van Leuven et al. have also used thiamet-G in a 
transgenic tauopathy model242. The Tau.P301L mice, in which 
the mutant tau transgene is driven by the thy1 gene promoter, 
were treated for approximately 10 weeks with this inhibitor in 85 
drinking water. The results are generally consistent with those 
observed by Yuzwa et al. insofar as treatment prevented motor 
defects as well as a loss in body weight. These authors also noted 
that no changes in phosphorylation of tau were observed, 
consistent with previous findings, but were unable to detect O-90 
GlcNAc on tau isolated from these mice. This surprising 
observation departs from earlier studies and is notable since O-
GlcNAc modification of tau from rodent tissue has been observed 
by several different groups using various methods including site 
specific antibodies66, 67, 71, 217 and mass spectrometry4, 71, 217. 95 
Nevertheless, these authors also observed that administration of 
OGA inhibitors resulted in a marked improvement in respiratory 
tract defects even over just a few days of administration. These 
observations are consistent with the idea mentioned earlier that 
OGA inhibition may well have other protective effects against tau 100 
toxicity independent of direct modification of tau. Finally, among 
the earliest papers on O-GlcNAc in AD is a report from Griffith 
and Schmidtz151 which indicates that O-GlcNAc levels in the 
cerebellum of AD brain tissues are the same as in control tissues, 
consistent with reports from the Gong group110, 150, but the study 105 
indicates that the cytoskeletal fraction within most other brain 
regions have increased levels of O-GlcNAc. These authors used 
different antibodies from those typically used but also used an 
enzymatic labeling method to detect O-GlcNAc to obtain similar 
results. The discrepancies between this study and other reports 110 
are not simple to reconcile since different analytical methods 
were used and post-mortem delay was not uniformly accounted 
for. Nevertheless, this data points to a clear need for further 
studies in the area of O-GlcNAc levels within AD brain tissues. 
Mostly useful would be studies aiming to correlate O-GlcNAc 115 
levels with disease progression within different brain regions 
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affected by hypometabolism with consideration of the post-
mortem delay. 
 In summary, the influence of O-GlcNAc in AD is now of clear 
interest to both academic and pharmaceutical communities. The 
potential protective effects of O-GlcNAc in other human 5 
neurodegenerative disorders such as ALS, PD, and Huntington’s 
disease are only just beginning to emerge and the next number of 
years will undoubtedly provide novel insight in this area. The fact 
that O-GlcNAc may play important roles in AD and these other 
neurodegenerative disorders suggests that it may play a generally 10 
protective role in the brain, which would be consistent with its 
high abundance in this organ. This protective role could become 
compromised during aging due to decreased glucose metabolism 
within the aging brain, and this could contribute, in part, to the 
etiology or progression of neurodegeneration. For this reason we 15 
speculate that pharmacological intervention, perhaps OGA 
inhibition, could have significant impact on various 
neurodegenerative disorders. Despite limited biochemical 
knowledge in this area, on the basis of the collective literature, 
we believe O-GlcNAc likely plays a critical role in regulating 20 
protein stability. We find it notable that O-GlcNAc is 
predominantly found on regions of proteins that are disordered 
since it well etablished that proteins with extensive regions of 
intrinsic disorder are often implicated in protein aggregation 
disorders including neurodegenerative diseases such as AD, PD, 25 
ALS, among others243. 
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